Edesa Biotech Overview
- Year Founded
-
2015

- Status
-
Public
- Employees
-
18

- Stock Symbol
-
EDSA

- Investments
-
1
- Share Price
-
$2.05
- (As of Tuesday Closing)
Edesa Biotech General Information
Description
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Contact Information
Website
www.edesabiotech.comCorporate Office
- 100 Spy Court
- Markham, Ontario L3R 5H6
- Canada
Corporate Office
- 100 Spy Court
- Markham, Ontario L3R 5H6
- Canada
Edesa Biotech Timeline
Edesa Biotech Stock Performance
As of 08-Jul-2025, Edesa Biotech’s stock price is $2.05. Its current market cap is $14.4M with 7.02M shares.
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.05 | $2.06 | $1.55 - $5.59 | $14.4M | 7.02M | 19.6K | -$1.55 |
Edesa Biotech Financials Summary
As of 31-Mar-2025, Edesa Biotech has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 30-Sep-2024 | FY 2023 30-Sep-2023 | FY 2022 30-Sep-2022 |
---|---|---|---|---|
EV | 16,480 | 12,449 | 6,989 | 1,477 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (5,725) | (6,137) | (8,480) | (17,493) |
Net Income | (5,838) | (6,170) | (8,374) | (17,549) |
Total Assets | 16,454 | 3,814 | 8,890 | 11,576 |
Total Debt | 0 | 20 | 94 | 19 |
Edesa Biotech Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Edesa Biotech Comparisons
Industry
Financing
Details
Edesa Biotech Competitors (6)
One of Edesa Biotech’s 6 competitors is Citius Pharma, a Formerly Angel backed company based in Cranford, NJ.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Citius Pharma | Formerly Angel backed | Cranford, NJ | ||||
Vicore Pharma Holding | Formerly VC-backed | Stockholm, Sweden | ||||
Eli Lilly | Corporation | Indianapolis, IN | ||||
Cipla | Corporation | Mumbai, India | ||||
Aclaris Therapeutics | Formerly VC-backed | Wayne, PA |
Edesa Biotech Signals
Edesa Biotech Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Edesa Biotech Acquisitions (1)
Edesa Biotech’s most recent deal was a Merger/Acquisition with Stellar Biotechnologies for . The deal was made on 07-Jun-2019.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Stellar Biotechnologies | 07-Jun-2019 | Merger/Acquisition | Biotechnology |
Edesa Biotech FAQs
-
When was Edesa Biotech founded?
Edesa Biotech was founded in 2015.
-
Where is Edesa Biotech headquartered?
Edesa Biotech is headquartered in Markham, Canada.
-
What is the size of Edesa Biotech?
Edesa Biotech has 18 total employees.
-
What industry is Edesa Biotech in?
Edesa Biotech’s primary industry is Drug Discovery.
-
Is Edesa Biotech a private or public company?
Edesa Biotech is a Public company.
-
What is Edesa Biotech’s stock symbol?
The ticker symbol for Edesa Biotech is EDSA.
-
What is the current stock price of Edesa Biotech?
As of 08-Jul-2025 the stock price of Edesa Biotech is $2.05.
-
What is the current market cap of Edesa Biotech?
The current market capitalization of Edesa Biotech is $14.4M.
-
Who are Edesa Biotech’s competitors?
Citius Pharma, Vicore Pharma Holding, Eli Lilly, Cipla, and Aclaris Therapeutics are some of the 6 competitors of Edesa Biotech.
-
What is Edesa Biotech’s annual earnings per share (EPS)?
Edesa Biotech’s EPS for 12 months was -$1.55.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »